Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?

References

• Emmanuel A, Goosey RW, Wiseman G, et al. Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D. BMC Gastroenterol. 2020;20(1):127. doi: 10.1186/s12876-020-01252-9
   PubMed Web of Science ®Google Scholar
• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2(1):16014. doi: 10.1038/nrdp.2016.14
   PubMedGoogle Scholar
• Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35. doi: 10.1186/s12955-017-0611-2
   PubMed Web of Science ®Google Scholar
• Törnblom H, Goosey R, Wiseman G, et al. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: results from patient and healthcare professional surveys. United Eur Gastroenterol J. 2018;6(9):1417–1427. doi: 10.1177/2050640618787648
   PubMed Web of Science ®Google Scholar
• Camilleri M, Dilmaghani S. Update on treatment of abdominal pain in irritable bowel syndrome: a narrative review. Pharmacol Ther. 2023;245:108400. doi: 10.1016/j.pharmthera.2023.108400
   PubMed Web of Science ®Google Scholar
• Lembo A, Sultan S, Chang L, et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137–151. doi: 10.1053/j.gastro.2022.04.017
   PubMed Web of Science ®Google Scholar
• Savarino E, Zingone F, Barberio B, et al. Functional bowel disorders with diarrhoea: clinical guidelines of the united European gastroenterology and European society for neurogastroenterology and motility. UEG Journal. 2022;10(6):556–584. doi: 10.1002/ueg2.12259
   Google Scholar
• Goodoory VC, Tuteja AK, Black CJ, et al. Systematic review and meta-analysis: efficacy of mesalamine in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2023. in press. doi: 10.1016/j.cgh.2023.02.014
   Web of Science ®Google Scholar
• Gunn D, Topan R, Barnard L, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther. 2023;57(11):1258–1271. doi: 10.1111/apt.17426
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18(1):5. doi: 10.1186/s12876-017-0734-2
   PubMedGoogle Scholar
• Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74–82. doi: 10.1136/gutjnl-2018-318160
   PubMed Web of Science ®Google Scholar
• Sciumè GD, Berti G, Lambiase C, et al. Misinterpreting diarrhea-predominant irritable bowel syndrome and functional diarrhea: pathophysiological highlights. J Clin Med. 2023;12(18):5787. doi: 10.3390/jcm12185787
   PubMed Web of Science ®Google Scholar
• Szymaszkiewicz A, Malkiewicz A, Storr M, et al. The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. J Physiol Pharmacol. 2019;70:15–24. doi: 10.26402/jpp.2019.1.01
   Web of Science ®Google Scholar
• Nee J, Salley K, Ludwig AG, et al. Randomized clinical trial: crofelemer treatment in women with diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2019;10(12):e00110. doi: 10.14309/ctg.0000000000000110
   PubMed Web of Science ®Google Scholar
• Howell CA, Kemppinen A, Allgar V, et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022;71(12):2430–2438. doi: 10.1136/gutjnl-2022-327293
   PubMed Web of Science ®Google Scholar
• Villanacci V, Casella G, Bassotti G. The spectrum of drug-related colitides: important entities, though frequently overlooked. Dig Liver Dis. 2011;43(7):523–528.
   PubMedGoogle Scholar
• El-Salhy M. Is irritable bowel syndrome an organic disorder? WJG. 2014;20(2):384–400. doi: 10.3748/wjg.v20.i2.384
   PubMed Web of Science ®Google Scholar
• Bassotti G, Villanacci V, Fisogni S, et al. Enteric glial cells and their role in gastrointestinal motor abnormalities: introducing the neuro-gliopathies. WJG. 2007;13(30):4035–4041. doi: 10.3748/wjg.v13.i30.4035
   PubMed Web of Science ®Google Scholar
• Bassotti G, Villanacci V, Antonelli E, et al. Enteric glial cells: new players in gastrointestinal motility? Lab Invest. 2007;87(7):628–632. doi: 10.1038/labinvest.3700564
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen N, Niu F, et al. Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs. Int J Colorectal Dis. 2022;37(11):2263–2276. doi: 10.1007/s00384-022-04261-0
   PubMed Web of Science ®Google Scholar
• Colomier E, Algera J, Melchior C. Pharmacological therapies and their clinical targets in irritable bowel syndrome with diarrhea. Front Pharmacol. 2021;11:629026. doi: 10.3389/fphar.2020.629026
   PubMed Web of Science ®Google Scholar